Last reviewed · How we verify
Ondansetron orodispersible film twice
Ondansetron orodispersible film twice is a Small molecule drug developed by Chongqing University Cancer Hospital. It is currently FDA-approved.
Ondansetron orodispersible film, marketed by Chongqing University Cancer Hospital, is an established product in the antiemetic market. The key composition patent expires in 2028, providing a significant period of market exclusivity. However, the lack of detailed primary trial results and revenue data poses a risk in assessing its full market potential and competitive positioning.
At a glance
| Generic name | Ondansetron orodispersible film twice |
|---|---|
| Sponsor | Chongqing University Cancer Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ondansetron orodispersible film twice CI brief — competitive landscape report
- Ondansetron orodispersible film twice updates RSS · CI watch RSS
- Chongqing University Cancer Hospital portfolio CI